Search Results - "Albanell, J"

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients by Vidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., Vidal, Y., Candamio, S., Vázquez, F., Ruiz, J., Guix, M., Visa, L., Sikri, V., Albanell, J., Bellosillo, B., López, R., Montagut, C.

“…RAS assessment is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however,…”
Get full text

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study by Alba, E., Calvo, L., Albanell, J., De la Haba, J.R., Arcusa Lanza, A., Chacon, J.I., Sanchez-Rovira, P., Plazaola, A., Lopez Garcia-Asenjo, J.A., Bermejo, B., Carrasco, E., Lluch, A.

“…Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully…”
Get full text

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study by Alba, E., Chacon, J. I., Lluch, A., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Segui, M. A., Ribelles, N., Alvarez, R., Sanchez-Muñoz, A., Sanchez, R., Garcia-Asenjo, J. A. Lopez, Rodriguez-Martin, C., Escudero, M. J., Albanell, J.

“…Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II…”
Get full text

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types by Baselga, J, Rischin, D, Ranson, M, Calvert, H, Raymond, E, Kieback, D G, Kaye, S B, Gianni, L, Harris, A, Bjork, T, Averbuch, S D, Feyereislova, A, Swaisland, H, Rojo, F, Albanell, J

“…To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its…”
Get full text

Mechanism of action of anti-HER2 monoclonal antibodies by Baselga, J., Albanell, J.

“…The search for new methods of treating cancer, combined with advances in our understanding of carcinogenesis, molecular biology and technology, has resulted in…”
Get full text

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) by Albanell, J., Martínez, M.T., Ramos, M., O'Connor, M., de la Cruz-Merino, L., Santaballa, A., Martínez-Jañez, N., Moreno, F., Fernández, I., Alarcón, J., Virizuela, J.A., de la Haba-Rodríguez, J., Sánchez-Rovira, P., González-Cortijo, L., Margelí, M., Sánchez-Muñoz, A., Antón, A., Casas, M., Bezares, S., Rojo, F.

“…The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2…”
Get full text

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer by Rojo, F., García-Parra, J., Zazo, S., Tusquets, I., Ferrer-Lozano, J., Menendez, S., Eroles, P., Chamizo, C., Servitja, S., Ramírez-Merino, N., Lobo, F., Bellosillo, B., Corominas, J.M., Yelamos, J., Serrano, S., Lluch, A., Rovira, A., Albanell, J.

“…Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its…”
Get full text

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity by Bellmunt, J., González-Larriba, J.L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez-Gracia, J.L., Aguilar, G., Villanueva, X., Albanell, J., Calvo, A.

“…A strong rationale supports the role of antiangiogenic drugs in urothelial cancer. This trial was designed to assess the activity of sunitinib as first-line…”
Get full text

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology by Colomer, R., Aranda-López, I., Albanell, J., García-Caballero, T., Ciruelos, E., López-García, M. Á., Cortés, J., Rojo, F., Martín, M., Palacios-Calvo, J.

“…This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative…”
Get full text

Predicting response and survival in chemotherapy-treated triple-negative breast cancer by Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E

“…Background: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer…”
Get full text

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study by Martin, M., Fumoleau, P., Dewar, J.A., Albanell, J., Limentani, S.A., Campone, M., Chang, J.C., Patre, M., Strasak, A., de Haas, S.L., Xu, J., Garcia-Saenz, J.A.

“…Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies. This phase Ib/IIa study…”
Get full text

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab by Hardy-Werbin, M., Arpí, O., Taus, A., Rocha, P., Joseph-Pietras, D., Nolan, L., Danson, S., Griffiths, R., Lopez-Botet, M., Rovira, A., Albanell, J., Ottensmeier, C. H., Arriola, E.

“…Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers of…”
Get full text

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer by Albanell, J., González, A., Ruiz-Borrego, M., Alba, E., García-Saenz, J.A., Corominas, J.M., Burgues, O., Furio, V., Rojo, A., Palacios, J., Bermejo, B., Martínez-García, M., Limon, M.L., Muñoz, A.S., Martín, M., Tusquets, I., Rojo, F., Colomer, R., Faull, I., Lluch, A.

“…This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers…”
Get full text

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial by Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A

“…Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients…”
Get full text

Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents by Bellmunt, J, Albiol, S, Suárez, C, Albanell, J

“…Abstract M-VAC (cisplatin, methotrexate, adriamycin, vinblastine) combination chemotherapy has been the standard of care in fit patient with advanced…”
Get full text

Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells by MOLINA, Miguel A, CODONY-SERVAT, Jordi, ALBANELL, Joan, ROJO, Federico, ARRIBAS, Joaquin, BASELGA, Jose

“…HER2 is a ligand-less tyrosine kinase receptor of the ErbB family that is frequently overexpressed in breast cancer. It undergoes proteolytic cleavage that…”
Get full text

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines by Arriola, E, Cañadas, I, Arumí-Uría, M, Dómine, M, Lopez-Vilariño, J A, Arpí, O, Salido, M, Menéndez, S, Grande, E, Hirsch, F R, Serrano, S, Bellosillo, B, Rojo, F, Rovira, A, Albanell, J

“…Background: Small cell lung carcinoma (SCLC) has poor prognosis and remains orphan from targeted therapy. MET is activated in several tumour types and may be a…”
Get full text

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition by Albanell, J.

Get full text

Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer by Tormo Martin, E., Adam-Artigues, A., Garrido-Cano, I., Pineda Merlo, B., Pattanayak, B., Cabello, P., Albanell, J., Rojo, F., Lluch, A., Eroles, P.

Get full text

Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer by Garrido-Cano, I., Pattanayak, B., Adam-Artigues, A., Cabello, P., Pineda, B., Tormo, E., Albanell, J., Rojo, F., Lluch, A., Eroles, P.

Get full text